to instantly read 150+ free stories & 250-word summaries of all our stories

Second Place

Light at the end of the multi-decadal vaccine tunnel

The race for a rotavirus vaccine has forced the government to change the rules of the game in a booming vaccine market. Bharat Biotech has the first-mover advantage but Serum Institute could have the last laugh

04/05/17

Ruhi Kandhari

The lowest bidder will supply 60% of the vaccines, while the second lowest will meet the remaining government demand

On 28 March, the ministry of health closed its first bid to buy 14.5 million doses of rotavirus vaccine for Rs 104.13 crore

Bharat Biotech will supply Rotavac in 10-dose vials, which results in 35-40% wastage, ​while the Serum Institute intends supplying the vaccine in 2-dose vials

Both Bharat Biotech and the Serum Institute are trying to get pre-qualified with the WHO to enter the global supply chain

syringe-1884779_1920-1920x1152.jpg

Want to read a free 200 word summary?

The negotiation was a simple one. Vaccine makers needed an assured market, and the government, assured supply. Until recently, the lowest bidder for a government tender took it all. Not anymore. The supplier who scores the second place also has value. After a year of dialogue in 2016, there’s finally a consensus. The lowest bidder…

Read the full story. Subscribe now.

Also read our exhaustive coverage about Vaccines, Future of Retail and Ride Sharing

Why subscribe? Let us explain.

Already Registered?

Related stories

More stories in /Commentary & /Healthcare

See all in Healthcare & Reportage

This story is for subscribers only.
or

Read the full story. Subscribe now.

Also read our exhaustive coverage about Vaccines, Future of Retail and Ride Sharing

Why subscribe? Let us explain.

The selected story is available only for paid subscribers. Might want to change your mind!

Subscribe now

Already Registered?

Questions?

What is The Ken?

The Ken is a subscription-driven media site. We write one story a day (weekdays only). These stories have sharp, original insights on technology, business, science and healthcare from India.

Why do I have to sign up to read your stories?

Our stories are not free. Well, some select stories are. But, a significant part of what we write at The Ken is for subscribers only. We put in a lot of effort and resources in writing our stories and believe that you must pay for good journalism.
Hence, our three plans. 1) The annual membership
2) The free sign up
3) The recurring quarterly subscription

On journalism and why you should pay for it, if you haven’t already seen it, here’s a great explainer from John Oliver.

So, one must pay for journalism?

Yes.

How many stories will I get if I take an annual membership?

790+ stories.

And, in the free sign up?

Four stories every month.

Do I get a refund?

We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am not getting my daily emails. Do I have to whitelist emails from The Ken?

An added benefit of your subscription (free/paid) are the daily personalised emails. These emails, at times, might end up in your spam/junk folder due to emojis, attachments or images. In case you’re not receiving these emails, it might help to whitelist us. If the problem still persists, write to us at [email protected].

Why am I unable to access the archives?

Full and unrestricted access to our archives is a feature of our annual membership.

My payment is not going through, what can I do?

Please write to us at [email protected] detailing the payment error or queries.

See all FAQs

    See all results for Ken

    No results found for Ken.